Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
In this trial we test the hypothesis that PCI and bivalirudin is superior to heparin alone
(according to local protocol) in reducing death, MI, and major bleeding in patients with
NSTEMI or STEMI at 180 days (primary end point), treated with ticagrelor or prasugrel.